Statement: One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia.
Primary_evidence: Adverse Events 1:   Total: 13/34 (38.24%)   Anemia 3/34 (8.82%)   Diarrhea 7/34 (20.59%)   Nausea 2/34 (5.88%)   Sepsis 1/34 (2.94%)   Urinary tract infection 1/34 (2.94%)   Alkaline phosphatase increased 1/34 (2.94%)   Neutrophil count decreased 2/34 (5.88%)   Dehydration 1/34 (2.94%)   Headache 1/34 (2.94%)   Thromboembolic event 1/34 (2.94%)